CalciMedica Appoints New CMO, Elects Director
Ticker: CALC · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1534133
| Field | Detail |
|---|---|
| Company | Calcimedica, INC. (CALC) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, filing
TL;DR
CalciMedica brings in a new CMO and adds a director to the board.
AI Summary
CalciMedica, Inc. announced on August 27, 2024, the appointment of Dr. Robert J. Valeri as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also reported on the submission of matters to a vote of security holders and filed financial statements and exhibits.
Why It Matters
These executive and board changes could signal strategic shifts or new directions for the company's leadership and governance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- CalciMedica, Inc. (company) — Registrant
- Dr. Robert J. Valeri (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Elected to Board of Directors
- August 27, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Robert J. Valeri has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Jennifer L. Jones has been elected to the Board of Directors.
What is the exact name of the registrant?
The exact name of the registrant is CalciMedica, Inc.
On what date was this report filed?
This report was filed on August 27, 2024.
What are the main items reported in this 8-K?
This 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 833 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-08-27 16:05:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CALC The Nasdaq
Filing Documents
- d884220d8k.htm (8-K) — 37KB
- d884220dex101.htm (EX-10.1) — 158KB
- 0001193125-24-207754.txt ( ) — 358KB
- calc-20240827.xsd (EX-101.SCH) — 2KB
- calc-20240827_lab.xml (EX-101.LAB) — 18KB
- calc-20240827_pre.xml (EX-101.PRE) — 11KB
- d884220d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 CalciMedica, Inc. 2023 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 27, 2024 CalciMedica, Inc. By: /s/ A. Rachel Leheny, Ph.D. Name: A. Rachel Leheny, Ph.D. Title: Chief Executive Officer